Notwithstanding promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from PBMs. These insurers are frequently creating obstacles to access, including significant expense criteria and approval processes that hinder patient access. Analysts believ